Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the
“Company”), a leading genomics-driven health sciences company,
today announced financial results for the second quarter ended June
30, 2023, along with recent business updates.
Second Quarter 2023 Financial
Highlights
-
Revenue from continuing operations of US$5.7 million
-
Adjusted EBITDA from continuing operations of US$(5.3) million
-
Cash and other short-term assets1 of US$214.5 million as of June
30, 2023
First Half 2023 Financial
Highlights
-
Revenue from continuing operations of US$11.6 million
-
Adjusted EBITDA from continuing operations of US$(15.1)
million
"We've always maintained that 2023 would be a
transformative year for Prenetics, and our recent strides
underscore that belief. We've channelled significant investments
into areas where we see not just potential, but a clear path to
dominance. Our collaboration with Prof. Dennis Lo, particularly in
the realm of early cancer detection, stands as a testament to our
commitment and vision. Today, our future business strategy is
crystallized into three distinct yet interconnected units:
prevention, early cancer detection, and targeted therapy. I am both
extremely excited and optimistic about the trajectory we're on, and
I believe that the best is yet to come for Prenetics," said
Danny Yeung, Chief Executive Officer and Co-Founder of
Prenetics.
______________________________
1 Represents current assets, including cash and
cash equivalents totaling US$177.2 million, financial assets at
fair value through profit or loss of US$13.6 million, and trade
receivables of US$5.6 million, amongst other accounting line items
under current assets.
Recent Highlights
- Completed transaction with Prof. Dennis Lo for Insighta as a
50/50 Joint Venture for Multi-Cancer Early Detection in July 2023.
Prenetics provided US$100m in consideration, with US$80m in cash
and US$20m of shares in Prenetics. Initial clinical trial data is
promising. A large multi-country overseas clinical trial is set to
begin in early 2024.
- ACT Genomics is expected to launch a 500-gene panel and a
100-gene panel comprehensive genomic profiling “liquid” biopsy test
by the fourth quarter of 2023.
- ACT Genomics product development work continues for a Minimal
Residual Disease (MRD) test is expected to be rolled out by Q2
2024.
- Multiple distribution and partnership deals are being discussed
for Southeast Asia and in the Middle East. More details will be
shared once available.
- Significant improvement in operational efficiency and cost
optimization, reducing adjusted EBITDA from continuing operations
from a loss of US$(9.8) million in the first quarter of 2023 to
US$(5.3) million in the current quarter with further reductions
expected in the second half of 2023.
About Prenetics
Prenetics (NASDAQ:PRE), a leading genomics-driven health
sciences company, is revolutionizing prevention, early detection,
and treatment. Our prevention arm, CircleDNA, uses whole exome
sequencing to offer the world's most comprehensive consumer DNA
test. Insighta, our US$200 million joint venture with renowned
scientist Prof. Dennis Lo, underscores our unwavering commitment to
saving lives through pioneering multi-cancer early detection
technologies. Insighta plans to introduce Presight for lung and
liver cancers in 2025, and to expand with Presight One for 10+
cancers in 2027. Lastly, ACT Genomics, our treatment unit, is the
first Asia-based company to achieve FDA clearance for comprehensive
genomic profiling of solid tumors via ACTOnco. Each of Prenetics'
units synergistically enhances our global impact on health, truly
embodying our commitment to 'enhancing life through science’. To
learn more about Prenetics, please visit www.prenetics.com
Investor Relations Contact:
investors@prenetics.com
Forward-Looking StatementsThis
press release contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Statements that are not
historical facts, including statements about the Company's goals,
targets, projections, outlooks, beliefs, expectations, strategy,
plans, objectives of management for future operations of the
Company, and growth opportunities are forward-looking statements.
In some cases, forward-looking statements can be identified by
words or phrases such as "may," "will," "expect," "anticipate,"
"target," "aim," "estimate," "intend," "plan," "believe,"
"potential," "continue," "is/are likely to" or other similar
expressions. Forward-looking statements are based upon estimates
and forecasts and reflect the views, assumptions, expectations, and
opinions of the Company, which involve inherent risks and
uncertainties, therefore they should not be relied upon as being
necessarily indicative of future results. A number of factors could
cause actual results to differ materially from those contained in
any forward-looking statement, including but not limited to: the
Company’s ability to further develop and grow its business,
including new products and services; its ability to execute on its
new business strategy in genomics, precision oncology, and
specifically, early detection for cancer; the results of case
control studies and/or clinical trials; and its ability to identify
and execute on M&A opportunities, especially in precision
oncology. In addition to the foregoing factors, you should also
carefully consider the other risks and uncertainties described in
the “Risk Factors” section of the Company’s most recent
registration statement on Form F-1 and the prospectus therein, and
the other documents filed by the Company from time to time with the
U.S. Securities and Exchange Commission. All information provided
in this press release is as of the date of this press release, and
the Company does not undertake any duty to update such information,
except as required under applicable law.
Basis of Presentation
Unaudited Financial Information and Non-IFRS
Financial Measures has been provided in the financial statements
tables included at the end of this press release. An explanation of
these measures is also included below under the heading “Unaudited
Financial Information and Non-IFRS Financial Measures.”
Unaudited Financial Information
and Non-IFRS Financial Measures
To supplement Prenetics’ consolidated financial
statements prepared in accordance with International Financial
Reporting Standards (“IFRS”), the Company is providing non-IFRS
measures, adjusted EBITDA from continuing operations, adjusted
gross profit from continuing operations and adjusted (loss)/profit
attributable to equity shareholders of Prenetics. These non-IFRS
financial measures are not based on any standardized methodology
prescribed by IFRS and are not necessarily comparable to
similarly-titled measures presented by other companies. Management
believes these non-IFRS financial measures are useful to investors
in evaluating the Company's ongoing operating results and
trends.
Management is excluding from some or all of its
non-IFRS results (1) Employee equity-settled share-based payment
expenses, (2) depreciation and amortization, (3) finance income and
exchange gain or loss, net, and (4) certain items that may not be
indicative of our business, results of operations, or outlook,
including but not limited to non-cash and/ or non-recurring items.
These non-IFRS financial measures are limited in value because they
exclude certain items that may have a material impact on the
reported financial results. Management accounts for this limitation
by analyzing results on an IFRS basis as well as a non-IFRS basis
and also by providing IFRS measures in the Company's public
disclosures.
In addition, other companies, including
companies in the same industry, may not use the same non-IFRS
measures or may calculate these metrics in a different manner than
management or may use other financial measures to evaluate their
performance, all of which could reduce the usefulness of these
non-IFRS measures as comparative measures. Because of these
limitations, the Company's non-IFRS financial measures should not
be considered in isolation from, or as a substitute for, financial
information prepared in accordance with IFRS. Investors are
encouraged to review the non-IFRS reconciliations provided in the
tables captioned “Reconciliation of loss from operations from
continuing operations under IFRS and adjusted EBITDA from
continuing operations (Non-IFRS)”, “Reconciliation of gross profit
from continuing operations under IFRS and adjusted gross profit
from continuing operations (Non-IFRS)” and “Reconciliation of
(loss)/profit attributable to equity shareholders of Prenetics
under IFRS and adjusted (loss)/profit attributable to equity
shareholders of Prenetics (Non-IFRS)” set forth at the end of this
document.
|
|
|
PRENETICS GLOBAL LIMITED |
|
Unaudited consolidated statements of financial
position |
|
(Expressed in United States dollars unless otherwise
indicated) |
|
|
|
|
|
|
|
|
|
June 30, |
|
March 31, |
|
December 31, |
|
|
2023 |
|
2023 |
|
2022 |
|
|
$ |
|
$ |
|
$ |
| Assets |
|
|
|
|
|
| Property, plant and
equipment |
10,031,570 |
|
11,809,757 |
|
13,102,546 |
| Intangible assets |
14,101,566 |
|
14,463,400 |
|
14,785,875 |
| Goodwill |
33,800,276 |
|
33,800,276 |
|
33,800,276 |
| Interests in associates |
559,193 |
|
677,339 |
|
788,472 |
| Deferred tax assets |
7,631 |
|
7,626 |
|
243,449 |
| Deferred expenses |
7,097,641 |
|
5,119,170 |
|
6,307,834 |
| Other non-current assets |
741,816 |
|
1,064,194 |
|
1,292,462 |
| Non-current
assets |
66,339,693 |
|
66,941,762 |
|
70,320,914 |
| |
|
|
|
|
|
| Deferred expenses |
8,588,431 |
|
4,547,611 |
|
4,577,255 |
| Inventories |
3,768,880 |
|
3,420,013 |
|
4,534,072 |
| Trade receivables |
5,636,969 |
|
5,718,516 |
|
41,691,913 |
| Deposits, prepayments and
other receivables |
5,594,273 |
|
6,488,436 |
|
6,889,114 |
| Amount due from an
associate |
138,781 |
|
181,942 |
|
- |
| Financial assets at fair value
through profit or loss |
13,593,201 |
|
17,537,608 |
|
17,537,608 |
| Short-term deposits |
- |
|
19,872,581 |
|
19,920,160 |
| Cash and cash equivalents |
177,179,297 |
|
166,335,875 |
|
146,660,195 |
| Current
assets |
214,499,832 |
|
224,102,582 |
|
241,810,317 |
| Total
assets |
280,839,525 |
|
291,044,344 |
|
312,131,231 |
| |
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
| Deferred tax liabilities |
2,694,720 |
|
2,924,369 |
|
3,185,440 |
| Warrant liabilities |
1,822,139 |
|
2,314,609 |
|
3,574,885 |
| Lease liabilities |
3,255,461 |
|
3,627,663 |
|
3,763,230 |
| Other non-current
liabilities |
823,082 |
|
830,562 |
|
949,701 |
| Non-current
liabilities |
8,595,402 |
|
9,697,203 |
|
11,473,256 |
| |
|
|
|
|
|
| Trade payables |
4,226,392 |
|
7,505,724 |
|
7,291,133 |
| Accrued expenses and other
current liabilities |
19,349,105 |
|
6,460,445 |
|
15,611,421 |
| Contract liabilities |
3,703,874 |
|
4,917,268 |
|
5,674,290 |
| Lease liabilities |
2,779,193 |
|
2,779,426 |
|
2,882,933 |
| Liabilities for puttable
financial instrument2 |
13,435,228 |
|
17,459,600 |
|
17,138,905 |
| Tax payable |
8,534,527 |
|
8,692,193 |
|
8,596,433 |
| Current
liabilities |
52,028,319 |
|
47,814,656 |
|
57,195,115 |
| Total
liabilities |
60,623,721 |
|
57,511,859 |
|
68,668,371 |
| |
|
|
|
|
|
| Equity |
|
|
|
|
|
| Share capital3 |
15,791 |
|
15,882 |
|
13,698 |
| Reserves |
215,291,050 |
|
228,232,194 |
|
237,050,429 |
| Total equity attributable to
equity shareholders of the Company |
215,306,841 |
|
228,248,076 |
|
237,064,127 |
| Non-controlling interests |
4,908,963 |
|
5,284,409 |
|
6,398,733 |
| Total
equity |
220,215,804 |
|
233,532,485 |
|
243,462,860 |
| Total equity and
liabilities |
280,839,525 |
|
291,044,344 |
|
312,131,231 |
_________________________________
2 In connection with the acquisition of ACT
Genomics, the remaining shareholders of ACT Genomics - representing
25.61% of the fully diluted shareholding of ACT Genomics that
Prenetics does not own - were granted put options which allow these
remaining shareholders to put their remaining shares to Prenetics
under certain conditions. The liabilities arising from such put
option are recorded as liabilities for puttable financial
instrument, and are valued at the present value of the exercise
price of the put option.
3 Represents number of authorized and issued
shares as follows:
|
|
June 30, |
|
March 31, |
|
December 31, |
|
|
2023 |
|
2023 |
|
2022 |
|
|
|
|
|
|
|
|
Number of authorized shares of $0.0001 each |
500,000,000 |
|
500,000,000 |
|
500,000,000 |
|
|
|
|
|
|
|
|
Number of issued shares |
157,905,434 |
|
158,820,280 |
|
136,983,110 |
|
|
|
PRENETICS GLOBAL LIMITED |
|
Unaudited consolidated statements of profit or loss and
other comprehensive income |
|
(Expressed in United States dollars unless otherwise
indicated) |
|
|
|
|
|
|
|
For the six months ended |
|
|
June 30, |
|
|
June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
|
$ |
|
$ |
|
|
|
|
(Restated) |
| Continuing
operations |
|
|
|
| Revenue |
11,600,319 |
|
|
8,291,318 |
|
| Direct costs |
(6,988,941 |
) |
|
(5,524,587 |
) |
| Gross
profit |
4,611,378 |
|
|
2,766,731 |
|
| Other income and other net
gain/(losses) |
2,629,405 |
|
|
(585,463 |
) |
| Selling and distribution
expenses4 |
(4,672,953 |
) |
|
(2,454,979 |
) |
| Research and development
expenses4 |
(6,177,592 |
) |
|
(3,941,463 |
) |
| Administrative and other
operating expenses4 |
(23,158,344 |
) |
|
(36,608,463 |
) |
| Loss from
operations |
(26,768,106 |
) |
|
(40,823,637 |
) |
| Fair value loss on financial
assets at fair value through profit or loss |
(3,944,407 |
) |
|
(1,659,343 |
) |
| Share-based payments on
listing5 |
- |
|
|
(89,546,601 |
) |
| Fair value loss on preference
shares liabilities |
- |
|
|
(60,091,353 |
) |
| Fair value gain/(loss) on
warrant liabilities |
1,752,746 |
|
|
(1,539,577 |
) |
| Share of losses of
associates |
(225,284 |
) |
|
- |
|
| Other finance costs |
(108,358 |
) |
|
(3,883,002 |
) |
| Loss before
taxation |
(29,293,409 |
) |
|
(197,543,513 |
) |
| Income tax credit |
268,827 |
|
|
1,971,231 |
|
| Loss from continuing
operations |
(29,024,582 |
) |
|
(195,572,282 |
) |
| Discontinued
operation |
|
|
|
| (Loss)/profit from
discontinued operation, net of tax6 |
(4,156,608 |
) |
|
18,409,191 |
|
| Loss for the
period |
(33,181,190 |
) |
|
(177,163,091 |
) |
| |
|
|
|
| Other comprehensive
income for the period |
|
|
|
| Item that may be reclassified
subsequently to profit or loss: |
|
|
|
| Exchange difference on
translation of: |
|
|
|
| - financial statements of
subsidiaries outside Hong Kong |
1,157,683 |
|
|
(4,775,936 |
) |
| Total comprehensive income for
the period |
(32,023,507 |
) |
|
(181,939,027 |
) |
| |
|
|
|
| Loss attributable
to: |
|
|
|
| Equity shareholders of
Prenetics |
(32,206,003 |
) |
|
(177,163,044 |
) |
| Non-controlling interests |
(975,187 |
) |
|
(47 |
) |
| |
(33,181,190 |
) |
|
(177,163,091 |
) |
| |
|
|
|
| Total comprehensive
income attributable to: |
|
|
|
| Equity shareholders of
Prenetics |
(30,533,737 |
) |
|
(181,938,980 |
) |
| Non-controlling interests |
(1,489,770 |
) |
|
(47 |
) |
| |
(32,023,507 |
) |
|
(181,939,027 |
) |
| |
|
|
|
| Loss per
share: |
|
|
|
| Basic |
(0.20 |
) |
|
(3.57 |
) |
| Diluted |
(0.20 |
) |
|
(3.57 |
) |
| |
|
|
|
| Loss per share -
Continuing operations: |
|
|
|
| Basic |
(0.18 |
) |
|
(3.94 |
) |
| Diluted |
(0.18 |
) |
|
(3.94 |
) |
| |
|
|
|
| Weighted average
number of common shares: |
|
|
|
| Basic |
158,656,029 |
|
|
49,616,648 |
|
| Diluted |
158,656,029 |
|
|
49,616,648 |
|
|
|
|
PRENETICS GLOBAL LIMITED |
|
Unaudited consolidated statements of profit or loss and
other comprehensive income |
|
(Expressed in United States dollars unless otherwise
indicated) |
|
|
|
|
|
|
|
|
|
For the three months ended |
|
|
June 30, |
|
|
March 31, |
|
|
June 30, |
|
|
|
2023 |
|
|
2023 |
|
|
2022 |
|
|
|
$ |
|
$ |
|
$ |
|
|
|
|
(Restated) |
|
(Restated) |
| Continuing
operations |
|
|
|
|
|
| Revenue |
5,695,579 |
|
|
5,904,740 |
|
|
4,183,499 |
|
| Direct costs |
(3,559,119 |
) |
|
(3,429,822 |
) |
|
(2,822,908 |
) |
| Gross
profit |
2,136,460 |
|
|
2,474,918 |
|
|
1,360,591 |
|
| Other income and other net
gain/(losses) |
1,406,281 |
|
|
1,223,124 |
|
|
(556,361 |
) |
| Selling and distribution
expenses4 |
(2,171,640 |
) |
|
(2,501,313 |
) |
|
(1,132,136 |
) |
| Research and development
expenses4 |
(2,703,038 |
) |
|
(3,474,554 |
) |
|
(2,192,768 |
) |
| Administrative and other
operating expenses4 |
(10,834,043 |
) |
|
(12,324,301 |
) |
|
(20,267,592 |
) |
| Loss from
operations |
(12,165,980 |
) |
|
(14,602,126 |
) |
|
(22,788,266 |
) |
| Fair value loss on financial
assets at fair value through profit or loss |
(3,944,407 |
) |
|
- |
|
|
(1,659,343 |
) |
| Share-based payments on
listing5 |
- |
|
|
- |
|
|
(89,546,601 |
) |
| Fair value loss on preference
shares liabilities |
- |
|
|
- |
|
|
(31,815,352 |
) |
| Fair value gain/(loss) on
warrant liabilities |
492,470 |
|
|
1,260,276 |
|
|
(1,539,577 |
) |
| Share of losses of
associates |
(112,533 |
) |
|
(112,751 |
) |
|
- |
|
| Other finance costs |
(51,464 |
) |
|
(56,894 |
) |
|
(1,420,446 |
) |
| Loss before
taxation |
(15,781,914 |
) |
|
(13,511,495 |
) |
|
(148,769,585 |
) |
| Income tax
credit/(expense) |
245,877 |
|
|
22,950 |
|
|
(246,859 |
) |
| Loss from continuing
operations |
(15,536,037 |
) |
|
(13,488,545 |
) |
|
(149,016,444 |
) |
| Discontinued
operation |
|
|
|
|
|
| (Loss)/profit from
discontinued operation, net of tax6 |
(6,671,413 |
) |
|
2,514,805 |
|
|
4,839,249 |
|
| Loss for the
period |
(22,207,450 |
) |
|
(10,973,740 |
) |
|
(144,177,195 |
) |
| |
|
|
|
|
|
| Other comprehensive
income for the period |
|
|
|
|
|
| Item that may be reclassified
subsequently to profit or loss: |
|
|
|
|
|
| Exchange difference on
translation of: |
|
|
|
|
|
| - financial statements of
subsidiaries and associates outside Hong Kong |
1,794,185 |
|
|
(636,502 |
) |
|
(4,245,198 |
) |
| Total comprehensive income for
the period |
(20,413,265 |
) |
|
(11,610,242 |
) |
|
(148,422,393 |
) |
| |
|
|
|
|
|
| Loss attributable
to: |
|
|
|
|
|
| Equity shareholders of
Prenetics |
(21,807,573 |
) |
|
(10,398,430 |
) |
|
(144,177,194 |
) |
| Non-controlling interests |
(399,877 |
) |
|
(575,310 |
) |
|
(1 |
) |
| |
(22,207,450 |
) |
|
(10,973,740 |
) |
|
(144,177,195 |
) |
| |
|
|
|
|
|
| Total comprehensive
income attributable to: |
|
|
|
|
|
| Equity shareholders of
Prenetics |
(20,037,819 |
) |
|
(10,495,918 |
) |
|
(148,422,392 |
) |
| Non-controlling interests |
(375,446 |
) |
|
(1,114,324 |
) |
|
(1 |
) |
| |
(20,413,265 |
) |
|
(11,610,242 |
) |
|
(148,422,393 |
) |
| |
|
|
|
|
|
| Loss per
share: |
|
|
|
|
|
| Basic |
(0.14 |
) |
|
(0.07 |
) |
|
(2.91 |
) |
| Diluted |
(0.14 |
) |
|
(0.07 |
) |
|
(2.91 |
) |
| |
|
|
|
|
|
| Loss per share -
Continuing operations: |
|
|
|
|
|
| Basic |
(0.10 |
) |
|
(0.08 |
) |
|
(3.00 |
) |
| Diluted |
(0.10 |
) |
|
(0.08 |
) |
|
(3.00 |
) |
| |
|
|
|
|
|
| Weighted average
number of common shares: |
|
|
|
|
|
| Basic |
158,963,468 |
|
|
157,839,309 |
|
|
49,616,648 |
|
| Diluted |
158,963,468 |
|
|
157,839,309 |
|
|
49,616,648 |
|
______________________________
4 Includes equity-settled share-based payment
expenses (excluding share-based payment on listing) from continuing
operations as follows:
|
|
For the six months ended |
|
|
June 30, |
|
June 30, |
|
|
2023 |
|
2022 |
|
|
$ |
|
$ |
|
|
|
|
(Restated) |
|
Selling and distribution expenses |
103,868 |
|
31,424 |
|
Research and development expenses |
1,360,896 |
|
1,245,847 |
|
Administrative and other operating expenses |
4,731,546 |
|
16,489,378 |
|
Total equity-settled share-based payment expenses (excluding
share-based payment on listing) |
6,196,310 |
|
17,766,649 |
|
|
For the three months ended |
|
|
June 30, |
|
March 31, |
|
June 30, |
|
|
2023 |
|
2023 |
|
2022 |
|
|
$ |
|
$ |
|
$ |
|
|
|
|
(Restated) |
|
(Restated) |
|
Selling and distribution expenses |
58,613 |
|
45,255 |
|
23,745 |
|
Research and development expenses |
874,389 |
|
486,507 |
|
708,511 |
|
Administrative and other operating expenses |
2,340,502 |
|
2,391,044 |
|
9,511,007 |
|
Total equity-settled share-based payment expenses (excluding
share-based payment on listing) |
3,273,504 |
|
2,922,806 |
|
10,243,263 |
5 The acquisition of the net assets of Artisan
Acquisition Corp. (“Artisan”) on May 18, 2022 does not meet the
definition of a business under IFRS and has therefore been
accounted for as a share-based payment. The excess of fair value of
Prenetics shares issued over the fair value of Artisan’s
identifiable net assets acquired represents compensation for the
service of a stock exchange listing for its shares and is expensed
as incurred.
6 We ceased our COVID-19 testing business
entirely in 2023 Q2. As a result, COVID-19 testing business is
reported as a discontinued operation under IFRS 5 Non-current
Assets Held for Sale and Discontinued Operations. In accordance
with IFRS 5, the results of the discontinued operation have been
presented separately from the continuing operations in the
consolidated statements of profit or loss and other comprehensive
income. The comparative information in the consolidated statements
of profit or loss and other comprehensive income has also been
re-presented to show the results of discontinued operation
separately.
|
|
|
PRENETICS GLOBAL LIMITED |
|
Unaudited Financial Information and Non-IFRS Financial
Measures |
|
(Expressed in United States dollars unless otherwise
indicated) |
|
|
|
|
|
|
Reconciliation of loss from
operations from continuing operations under IFRS
and adjusted EBITDA from continuing operations
(Non-IFRS) |
|
|
|
|
|
|
|
For the six months ended |
|
|
June 30, |
|
|
June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
|
$ |
|
|
$ |
|
| |
|
|
(Restated) |
| Loss from operations
from continuing operations under IFRS |
(26,768,106 |
) |
|
(40,823,637 |
) |
| Employee equity-settled
share-based payment expenses |
6,237,845 |
|
|
17,960,605 |
|
| Depreciation and
amortization |
3,935,194 |
|
|
924,050 |
|
| Other strategic financing,
transactional expense and non-recurring expenses |
4,002,301 |
|
|
9,202,912 |
|
| Finance income, exchange gain
or loss, net |
(2,469,946 |
) |
|
703,368 |
|
| Adjusted EBITDA from
continuing operations (Non-IFRS) |
(15,062,712 |
) |
|
(12,032,702 |
) |
| |
|
|
|
|
Reconciliation of gross profit from
continuing operations under IFRS and adjusted gross
profit from continuing operations
(Non-IFRS) |
| |
|
|
|
| |
For the six months ended |
| |
June 30, |
|
|
June 30, |
|
| |
2023 |
|
|
2022 |
|
| |
$ |
|
|
$ |
|
| |
|
|
(Restated) |
| Gross profit from
continuing operations under IFRS |
4,611,378 |
|
|
2,766,731 |
|
| Depreciation and
amortization |
719,974 |
|
|
51,786 |
|
| Adjusted gross profit
from continuing operations (Non-IFRS) |
5,331,352 |
|
|
2,818,517 |
|
| |
|
|
|
|
Reconciliation of loss attributable to equity shareholders
of Prenetics under IFRS and adjusted (loss)/profit attributable to
equity shareholders of Prenetics (Non-IFRS) |
| |
|
|
|
| |
For the six months ended |
| |
June 30, |
|
|
June 30, |
|
| |
2023 |
|
|
2022 |
|
| |
$ |
|
|
$ |
|
| |
|
|
(Restated) |
| Loss attributable to
equity shareholders of Prenetics under IFRS |
(32,206,003 |
) |
|
(177,163,044 |
) |
| Employee equity-settled
share-based payment expenses |
6,237,845 |
|
|
22,344,081 |
|
| Other strategic financing,
transactional expense and non-recurring expenses |
9,917,705 |
|
|
10,549,874 |
|
| Share-based payment on
listing |
- |
|
|
89,546,601 |
|
| Fair value loss on preference
shares liabilities |
- |
|
|
60,091,353 |
|
| Fair value (gain)/loss on
warrant liabilities |
(1,752,746 |
) |
|
1,539,577 |
|
| Fair value loss on financial
assets at fair value through profit or loss |
3,944,407 |
|
|
1,659,343 |
|
| Adjusted (loss)/profit
attributable to equity shareholders of
Prenetics Non-IFRS) |
(13,858,792 |
) |
|
8,567,785 |
|
|
|
|
PRENETICS GLOBAL LIMITED |
|
Unaudited Financial Information and Non-IFRS Financial
Measures |
|
(Expressed in United States dollars unless otherwise
indicated) |
| |
|
|
|
|
|
|
Reconciliation of loss from operations from continuing
operations under IFRS and adjusted EBITDA from continuing
operations (Non-IFRS) |
| |
|
|
|
|
|
| |
For the three months ended |
|
|
June 30, |
|
|
March 31, |
|
|
June 30, |
|
| |
2023 |
|
|
2023 |
|
|
2022 |
|
| |
$ |
|
|
$ |
|
|
$ |
|
| |
|
|
(Restated) |
|
(Restated) |
| Loss from operations
from continuing operations under
IFRS |
(12,165,980 |
) |
|
(14,602,126 |
) |
|
(22,788,266 |
) |
| Employee equity-settled
share-based payment expenses |
3,296,861 |
|
|
2,940,984 |
|
|
10,215,945 |
|
| Depreciation and
amortization |
1,863,626 |
|
|
2,071,568 |
|
|
230,422 |
|
| Other strategic financing,
transactional expense and non-recurring expenses |
3,077,902 |
|
|
924,399 |
|
|
7,638,653 |
|
| Finance income, exchange gain
or loss, net |
(1,323,782 |
) |
|
(1,146,164 |
) |
|
671,596 |
|
| Adjusted EBITDA from
continuing operations (Non-IFRS) |
(5,251,373 |
) |
|
(9,811,339 |
) |
|
(4,031,650 |
) |
| |
|
|
|
|
|
|
Reconciliation of gross profit from continuing operations
under IFRS and adjusted gross profit from continuing operations
(Non-IFRS) |
| |
|
|
|
|
|
| |
For the three months ended |
| |
June 30, |
|
|
March 31, |
|
|
June 30, |
|
| |
2023 |
|
|
2023 |
|
|
2022 |
|
| |
$ |
|
|
$ |
|
|
$ |
|
| |
|
|
|
(Restated) |
|
|
(Restated) |
|
| Gross profit from
continuing operations under IFRS |
2,136,460 |
|
|
2,474,918 |
|
|
1,360,591 |
|
| Depreciation and
amortization |
335,648 |
|
|
384,326 |
|
|
26,729 |
|
| Adjusted gross profit
from continuing operations
(Non-IFRS) |
2,472,108 |
|
|
2,859,244 |
|
|
1,387,320 |
|
| |
|
|
|
|
|
|
Reconciliation of loss attributable to equity shareholders
of Prenetics under IFRS and adjusted (loss)/profit attributable to
equity shareholders of Prenetics (Non-IFRS) |
| |
|
|
|
|
|
| |
For the three months ended |
| |
June 30, |
|
|
March 31, |
|
|
June 30, |
|
| |
2023 |
|
|
2023 |
|
|
2022 |
|
| |
$ |
|
|
$ |
|
|
$ |
|
| |
|
|
(Restated) |
|
(Restated) |
| Loss attributable to
equity shareholders of Prenetics under
IFRS |
(21,807,573 |
) |
|
(10,398,430 |
) |
|
(144,177,194 |
) |
| Employee equity-settled
share-based payment expenses |
3,113,656 |
|
|
3,124,189 |
|
|
12,966,966 |
|
| Other strategic financing,
transactional expense and non-recurring expenses |
7,678,799 |
|
|
2,238,906 |
|
|
8,854,689 |
|
| Share-based payment on
listing |
- |
|
|
- |
|
|
89,546,601 |
|
| Fair value loss on preference
shares liabilities |
- |
|
|
- |
|
|
31,815,352 |
|
| Fair value (gain)/loss on warrant
liabilities |
(492,470 |
) |
|
(1,260,276 |
) |
|
1,539,577 |
|
| Fair value loss on financial
assets at fair value through profit or loss |
3,944,407 |
|
|
- |
|
|
1,659,343 |
|
| Adjusted (loss)/profit
attributable to equity shareholders of Prenetics
(Non-IFRS) |
(7,563,181 |
) |
|
(6,295,611 |
) |
|
2,205,334 |
|
Prenetics Global (NASDAQ:PRE)
過去 株価チャート
から 10 2024 まで 11 2024
Prenetics Global (NASDAQ:PRE)
過去 株価チャート
から 11 2023 まで 11 2024
